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PotentAbstract Cell cycle consists of different types of phases, transition from G1, S, G2, M. Inhibition
of associated CDKs like CDK9/Cyclin T1 complex, which are indirectly involved in the Cell cycle
progression in the form of transcription elongation, reduces diverse diseases such as Cardiac Hyper-
trophy, Alzheimer’s, Cancer, AIDS and Inflammation. Glide tool of the Schrodinger software
has been used for performing Structure Based Virtual Screening and Docking against Drug Bank
and MDPI database. The best hits were identified which go and bind in the active site of the target
where ATP binds for the activity. The ADMET, MM-GBSA and DFT analysis is also done for
the same. Compound 4-{4-[4-(3-aminopropoxy)phenyl]-1H-pyrazol-5-yl}-6-chlorobenzene-1,3-diol
(DB08045) was found to be more potent, novel and selective as an inhibitor. Hopefully compound
(DB08045) could be used as an anti-cancer agent for the treatment of life-threatening diseases.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Several diseases like Cancer and numerous Proliferative dis-
eases occurred because of the alteration in the Cell cycle.
The Cell cycle is controlled by the CDK family, which binds
with the Cyclin unit for its activation (Morgan, 1997). CDK
activation and regulation support cell division, changing the
transition state and entry into the mitosis phase (Nigg, 1995;
Vermeulen et al., 2003). Besides Cell cycle control some of
the CDKs take part in the controlling of the transcription pro-
cess (Chao et al., 2000). CDKs play different role such as
CDK2 play an essential role in the apoptosis, CDK5 role in
neuronal cell and CDK7, CDK8, CDK9 role in the transcrip-
tion process (Gray et al., 1999). The transcription process iser agent.
Figure 1 List of co-crystallized CDK9/Cyclin T1 inhibitors found in the Protein Data Bank.
2 A. Hussain et al.responsible for making mRNAs together with pre-initiation,
initiation, elongation and termination. Among all the phases,
the elongation phase is an extremely and vibrant step for reg-
ulating the transcription cycle (Sims et al., 2004; Loyer et al.,
2005; Fuda et al., 2009). Processing of the elongation phase,
the phosphorylation of the CDK substrate mechanism is cru-
cial (Suryadinata et al., 2010). Protein kinases control the
cellular signaling processes by performing catalyzed phospho
transfer reaction (Johnson et al., 1998; Traxler and Furet,
1999). One of the CDKs is CDK9, which is a cdc2-like kinase
involved in the transcription elongation phase with pairing of
Cyclin units and making P-TEFB complex (CDK9/Cyclin T1)
(Peng et al., 1998b). Cyclin K is also associated with the CDK9
and works as a CDK9 regulatory subunit that has been con-
firmed by the in vivo and in vitro studies and participates in
the cellular control of the gene expression (Fu et al., 1999;
Garriga and Grana, 2004). CDK9 is present in the two iso-
forms, one is CDK9 p42 and the other one is CDK9 p52, act-
ing similarly. Both are present in the mammalian cells and
show tissue specific expression pattern (Shore et al., 2003;
Liu and Herrmann, 2005). The cdc-2 related kinase having
motif Pro-Ile-Thr-Ala-Leu-Arg-Glu named PITALRE inter-
acts with their associated Cyclin units (Grana et al., 1994).
P-TEFB complex (CDK9/Cyclin T1) plays a significant role
for transcription elongation (Zhu et al., 1997; Wei et al.,
1998). Carboxy terminal domain is an important part of the
Cyclin T1, deletion of that part decreases the kinase action
and transcription activity around 10% (Zhu et al., 1997;
Peng et al., 1998a,b; Wei et al., 1998; Anand et al., 2007;
Baumli et al., 2008). P-TEFB controls the transcription pro-
cess with the activation of the CTD of the RNA polymerase
II (Chao et al., 2000). Phosphorylation of the threonine residue
in the CDK9 leads to the activation of the P-TEFB complex.
Thus CDK9/Cyclin T1 is involved in the Apoptosis, Cell dif-
ferentiation, Cell proliferation (Desai et al., 1992; De FalcoPlease cite this article in press as: Hussain, A. et al., Identification of novel inhibitor
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Ser 2 sites of the RNA polymerase II for the elongation of
the transcription process (Phatnani and Greenleaf, 2006;
Egloff and Murphy, 2008; Krystof et al., 2010). ATP compet-
itive inhibitor plays a crucial role for inquisitive the activity of
CDK9 (Kamb, 1995; Lander et al., 2001). In Cell cycle numer-
ous processes come about for the controlling of the CDK9 like
Cyclin unit binding, phosphorylation and inhibitory INK4
subunits (Pavletich, 1999). CDK9 is the main target for Cancer
prevention so that several inhibitors designed against the tar-
get and some of them show a promising binding affinity like
DRB, which make Halogen bond with the CDK9 kinase hinge
region (Baumli et al., 2010), 2-Anilino-4-(thiazol-5-yl) Pyrim-
idine (Wang et al., 2010), 4-Arylazo-3,5-diamino-1H-pyrazole
(Krystof et al., 2006), Roscovitine, CR8 (Bettayeb et al., 2010;
Berberich et al., 2011), Flavopiridol (Garriga and Grana,
2004; Schmerwitz et al., 2011), CAN-508 (Krystof et al., 2011).
Flavopiridol has a wide specificity for CDK kinase inhibition.
It blocks the transcription in the elongation phase and induces
Apoptosis in the cell (Chao et al., 2000; Schmerwitz et al.,
2011). Some of the Co-crystallized CDK9/Cyclin T1 inhibitors
are available in the Protein Data Bank targeting CDK9
(Krystof et al., 2012): Flavopiridol (1), DRB (2), CAN-508 (3),
2-amino-4-heteroaryl-pyrimidine (4) (Fig. 1).
CDK kinase modulators are moreover promising for
modulating the kinase activity via blocking Cell cycle progres-
sion (Senderowicz and Sausville, 2000). To date only 11 kinase
inhibitors received US Food and Drug Administration
approval as Cancer treatments (Zhang et al., 2009). Structure
Based Drug Design for development of Cell cycle inhibitor is
the right approach for the Cancer therapy (Davies et al.,
2002; Dickson and Schwartz, 2009).
Hence, it is very important to develop and discovery some
novel inhibitors, which can bind to the ATP binding site of the
CDK9 kinase and reduce some of the life-threatening diseasess against Cyclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer agent.
.003
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ative diseases.
SBVS technique is very important to find out the drug com-
pound very rapidly from the large library of the compounds in
the Medicinal Chemistry Research (McInnes, 2007;
Tuccinardi, 2009). Since the discovery of novel CDK9/Cyclin
T1 (P-TEFB) complex inhibitor, orderly computational tools
were used. Eight novel compounds were found from Drug Bank
and three fromMDPI database as CDK9 inhibitors using Struc-
ture Based Virtual Screening and Docking approach.
2. Materials and methods
2.1. Protein selection and preparation
CDK9/Cyclin T1 complex protein structure has been taken
from the Protein Data Bank (PDB ID: 3BLQ). Before going
to the docking procedure, the protein structure was prepared
using the Protein preparation wizard of the Schrodinger soft-
ware. A step by step procedure was used for the preparation.Figure 2 Structure Based Vi
Please cite this article in press as: Hussain, A. et al., Identification of novel inhibitor
Saudi Journal of Biological Sciences (2015), http://dx.doi.org/10.1016/j.sjbs.2015.10.The protein structure was loaded into the Prep wizard where
bond orders were assigned, after that hydrogen atoms were
added. In the last stage a restrained minimization was per-
formed with the RMSD cut off of 0.30 A˚ and OPLS-2005 force
field (Baumli et al., 2008).
2.2. Ligand preparation
The small molecules of the ligand were retrieved from the Drug
Bank and MDPI database. These molecules were prepared by
using the Ligprep module of the Schrodinger software. The
bond order and the bond angle were assigned, then minimiza-
tion was done by using OPLS-2005 force field. The Epik
option was used for keeping ligand in the correct protonation
state (Banks et al., 2005).
2.3. Grid preparation
The Glide protocol was used for generating the grid of the pro-
tein structure. The ATP binding site was selected as centroidrtual Screening workflow.
s against Cyclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer agent.
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Table 1 2D structure of the selected inhibitors from Drug Bank database and reference compounds respectively with their docking
scores.
Drug Bank id Compound structure Mol. Wt. Mol. formula Docking score
DB08045 360.814 C18H19ClN3O3
+ 14.072
DB01204 446.496 C22H30N4O6
2+ 13.456
DB07766 365.383 C20H19N3O4 11.807
DB01772 409.410 C22H20FN3O4 11.505
DB02594 227.217 C9H13N3O4 11.469
DB07715 270.237 C15H10O5 11.353
DB07163 311.333 C17H16FN4O
+ 10.826
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Table 1 (continued)
Drug Bank id Compound structure Mol. Wt. Mol. formula Docking score
DB08133 316.335 C14H12N4O3S 10.679
2-Amino-4-heteroaryl-pyrimidiner – – – 8.639
r= reference compound.
Table 2 2D structure of the selected inhibitors from MDPI database respectively with their docking scores.
MDPI id Compound structure Mol. Wt. Mol. formula Docking score
MDPI14871 362.417 C20H26O6 11.453
MDPI20746 302.236 C15H10O7 10.350
MDPI14352 272.210 C14H8O6 10.378
Identification of novel inhibitors 5for the CDK9 protein and scaling factor was selected as 1.0
and the partial charge cutoff was selected as the 0.25
(Friesner et al., 2006).
2.4. Preparation of the reference compounds
The Reference compounds were retrieved from the co-
crystallized structure of protein–ligand complexes from the
Protein Data Bank, after that ligand was prepared by using
the ligprep module of the Schrodinger software and docked
with the protein CDK9 kinase and that docked score and
already reported ligand were kept as a reference for finding
the best drug compound from the Drug Bank and the MDPI
database.
2.5. Virtual screening
High throughput virtual screening was performed against the
CDK9/Cyclin T1 complex. A total number of 22,401 ligand
compounds were taken from the MDPI database and 6858
ligand compounds were taken from the Drug Bank database.Please cite this article in press as: Hussain, A. et al., Identification of novel inhibitor
Saudi Journal of Biological Sciences (2015), http://dx.doi.org/10.1016/j.sjbs.2015.10.These compounds and the reference compounds were sub-
jected to the Lipinski filtration and reactive functionality.
The reference compounds were also incorporated in the data-
base. Glide maestro protocol was used for the virtual screen-
ing using Schrodinger software. It performed docking of the
drug compounds in the different phases like HTVS (High
throughput virtual screening), SP (Standard-precision), XP
(Extra-precision). The library contains a large number of
compounds so that after performing HTVS screening remain-
ing 10% was performed using the Standard-precision dock-
ing, and remaining 10% was performed using the Extra-
precision docking. The virtual screening workflow is shown
in Fig. 2.2.6. Density functional theory analysis
LUMO and HOMO energy poses showed the region where
small molecule accepts the electron during the complex forma-
tion and donates the electron during the complex formation.
The gap energy is defined as the difference between HOMO
and LUMO molecular orbital energy, that energy indicatess against Cyclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer agent.
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(a) (b)
(c) (d)
(e) (f)
Figure 3 Binding mode of the selected ligand in the active site of the CDK9/Cyclin T1 complex proposed by docking studies. (a) Binding
mode of the ligand DB08045. (b) Ligplot Interaction diagram of the DB08045 ligand. (c) Binding mode of the ligand DB01204.
(d) Binding mode of the ligand DB07766. (e) Binding mode of the ligand DB01772. (f) Binding mode of the ligand DB02594. (g) Binding
mode of the ligand DB07715. (h) Binding mode of the ligand DB07163. (i) Binding mode of the ligand DB08133. The inhibitors have
been shown in stick form and yellow dotted lines indicate the inhibitor protein H-bonding. The critical protein residues have been shown
in gray color.
6 A. Hussain et al.the excitation energy showing the stability and reactivity of the
compounds (Becke, 1993).
2.7. Drug like property analysis
The hits were selected for finding drug like properties. These
properties follow Lipinski’s rule of five. The properties which
have been considered are Molecular Weight (MW), Lipophilic-Please cite this article in press as: Hussain, A. et al., Identification of novel inhibitor
Saudi Journal of Biological Sciences (2015), http://dx.doi.org/10.1016/j.sjbs.2015.10ity (logP), Hydrogen Bond Acceptor (HBA), Hydrogen Bond
Donor (HBD), Human Oral Absorption (Lipinski et al., 2001).
2.8. MM-GBSA approach for drug-target binding energy estimation
Drug-Target binding energy was calculated by using Schrodin-
ger software. This binding energy estimates the stability of the
protein and the ligand complexes (Lyne et al., 2006).s against Cyclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer agent.
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(g) (h)
(i) 
Fig. 3 (continued)
Identification of novel inhibitors 73. Result and discussion
3.1. Database screening and docking against the target
Virtual screening and docking approach was used for finding
the novel lead compound. Drug Bank database and MDPI
database were selected for that. We found eight best lead com-
pounds from Drug Bank database and three best lead com-
pounds from MDPI database, which showed best binding
affinity with the target protein.
Compound DB08045 was found to be more potent and
selective, which interacts with the target protein active site resi-
dues. It makes H-bonding with residues (Cys106, Asp104,
Lys48, Ile25, Asn154, Asp167) with docking score 14.072.
The docking score is high and it covered the ATP binding site
completely. It means this lead compound tightly docked in the
active site of the target protein and showed good inhibition
property. The docking score for DB08045, DB01204,
DB07766, DB01772, and DB02594, DB07715, DB07163 and
DB08133 has been identified (Table 1). The same docking
and virtual screening procedure is used in MDPI database
and three best hits are found. The docking score for
MDPI14871, MDPI20746 and MDPI14352 has been shown
in Table 2. The docking and Ligplot interaction diagram gives
a better view of interaction between target and lead com-
pounds (Figs. 3 and 4).Please cite this article in press as: Hussain, A. et al., Identification of novel inhibitor
Saudi Journal of Biological Sciences (2015), http://dx.doi.org/10.1016/j.sjbs.2015.10.3.2. HOMOLUMO stability analysis of the screened compounds
Drug and protein interaction stability and contribution of
selected inhibitors were analyzed using HOMO and LUMO
for the Drug Bank database selected compounds (Table 3)
and MDPI database selected compounds (Table 4). The orbital
energy and gap energy between the two orbitals were esti-
mated. Molecular reactivity was an analysis of the drug candi-
date (Figs. 5 and 6). The lowest energy gap found for DB01772
is 0.10269 and the highest energy gap found for DB02594 is
0.18897 for Drug Bank selected compounds and 0.11703 and
0.14723 for MDPI selected compounds.
3.3. ADMET and drug-likeliness property analysis against
screened compounds
These selected hits were evaluated for the physiochemical
properties and drug likeliness properties. These selected hits
followed Lipinski’s rule of five. Evidence for drug like charac-
teristics, we selected various properties such as Molecular
weight (MW), Total solvent accessible surface, Hydrogen bond
acceptor (HBA), Hydrogen bond donor (HBD), Predicted
aqueous solubility and Human oral absorption were assessed.
The Total solvent accessible surface and Molecular weight
have been shown to be a very good descriptor for characteriz-
ing drug absorption, including intestinal absorption ands against Cyclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer agent.
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(C)
Figure 4 Binding mode of the selected ligand in the active site of the CDK9/Cyclin T1 complex proposed by docking studies. (a) Binding
mode of the ligand MDPI14871. (b) Binding mode of the ligand MDPI20746. (c) Binding mode of the ligand MDPI14352. The inhibitors
have been shown in stick form and yellow dotted lines indicate the inhibitor protein H-bonding. The critical protein residues have been
shown in gray color.
Table 3 Orbital energy of the selected inhibitors of the Drug
Bank database.
S.
No.
Compound
name
HOMO
energy
LUMO
energy
HLG
(eV)
1 DB08045 0.27511 0.16337 0.11174
2 DB01204 0.35700 0.24697 0.11003
3 DB07766 0.19160 0.08257 0.10903
4 DB01772 0.19318 0.09049 0.10269
5 DB02594 0.22590 0.03693 0.18897
6 DB07715 0.23425 0.09745 0.1368
7 DB07163 0.28094 0.16916 0.11178
8 DB08133 0.23122 0.05651 0.17471
Table 4 Orbital energy of the selected inhibitors of the MDPI
database
S.
No.
Compound
name
HOMO
energy
LUMO
energy
HLG
(eV)
1 MDPI14871 0.19363 0.05277 0.14086
2 MDPI20746 0.20836 0.06113 0.14723
3 MDPI14352 0.21861 0.10158 0.11703
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cules with their corresponding Drug Bank id and MDPI data-
base id has been given with their chemical properties. The
chemical properties of the drug bank hits are illustrated in
Table 5 and for MDPI hits are illustrated in Table 6.
3.4. Drug-target binding energy analysis against screened
compounds
Prime MM-GBSA (GB stands for Generalized Born) module of
the Schrodinger software is very useful for finding out the pro-
tein–ligand binding affinity. The selected protein–ligand com-
plexes were subjected to that module. It combines OPLS
molecular mechanics energies (EMM), surface generalized born
solvation model for polar solvation (GSGB), and a nonpolar sol-
vation term (GNP). The total free energy of binding calculation is:
DGbind ¼ Gcomplex  ðGprotein þ GligandÞ ð1Þ
DGbind: total binding free energy of complex, Gcomplex: total
energy of the complex, Gprotein: energy of the receptor without
ligand, Gligand: energy of the unbound ligand.
Where G ¼ EMM þ GSGB þ GNP ð2Þ
The binding free energy estimated for Drug Bank com-
pound complexes (Table 7) and for MDPI compound com-
plexes is illustrated in Table 8.s against Cyclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer agent.
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HOMO LUMO
DB08045
DB01204
DB07766
DB01772
DB02594
DB07715
DB07163
DB08133
Figure 5 Plot shows highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) of Drug Bank
screened selected compounds. The red color indicates positive electron density while blue color indicates negative electron density
respectively.
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HOMO LUMO
MDPI 14871 
MDPI 20746
MDPI 14352 
Figure 6 Plot shows highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) of MDPI screened
selected compounds. The red color indicates positive electron density while blue color indicates negative electron density respectively.
Table 5 Drug-like properties of the selected inhibitors from Drug Bank database.
S. No. Drug Bank ida Mol. Wt.b SASAc Human oral absorptiond HB donore HB acceptorf QP log Sg
1 DB08045 360.814 635.553 62.835 5 4.750 3.356
2 DB01204 446.496 741.991 24.671 4 9.900 1.112
3 DB07766 365.383 654.056 78.131 3 7.600 4.137
4 DB01772 409.410 606.405 75.572 4 7.400 3.784
5 DB02594 227.217 424.935 50.835 4 9.100 1.529
6 DB07715 270.237 477.959 68.395 1 4.250 3.048
7 DB07163 311.333 543.171 65.815 5 4.500 2.217
8 DB08133 316.335 557.232 62.073 3 7.000 3.355
a Drug Bank inhibitors id.
b Molecular weight (acceptable range is: 6500).
c Total solvent accessible surface area (acceptable range is: 300–1000).
d Human oral absorption (acceptable range is: <25% less & >80% high).
e Hydrogen bond donor (acceptable range is: 65).
f Hydrogen bond acceptor (acceptable range is: 610).
g Predicted aqueous solubility (acceptable range is: 6.5 to 0.5).
Table 6 Drug-like properties of the selected inhibitors from MDPI database.
S. No. MDPI ida Mol. Wt.b SASAc Human oral absorptiond HB donore HB acceptorf QP log Sg
1 MDPI14871 362.417 588.370 75.441 4 5.700 3.573
2 MDPI20746 302.236 531.625 53.717 4 5.250 3.096
3 MDPI14352 272.210 454.633 61.573 1 4.000 2.565
a MDPI database inhibitors id.
b Molecular weight (acceptable range is: 6500).
c Total solvent accessible surface area (acceptable range is: 300–1000).
d Human oral absorption (acceptable range is: <25% less & >80% high).
e Hydrogen bond donor (acceptable range is: 65).
f Hydrogen bond acceptor (acceptable range is: 610).
g Predicted aqueous solubility (acceptable range is: 6.5 to 0.5).
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Table 7 Prime MM-GBSA energy calculation result of the selected inhibitors from Drug Bank database with the target.
S. No. Compound ida DG bindb Gevdwc Gcould
1 DB08045 64.55 35.05 40.47
2 DB01204 84.11 43.18 62.70
3 DB07766 67.25 38.84 27.38
4 DB01772 62.04 46.67 9.48
5 DB02594 40.58 29.45 20.05
6 DB07715 60.48 29.73 24.52
7 DB07163 59.18 36.42 24.68
8 DB08133 55.15 34.93 27.31
a Inhibitors id from Drug Bank database.
b Free binding energy.
c Van der Waal energy.
d Coulomb energy.
Table 8 Prime MM-GBSA energy calculation result of the selected inhibitors from MDPI database with the target.
S. No. Compound ida DG bindb Gevdwc Gcould
1 MDPI14871 74.98 36.46 20.06
2 MDPI20746 60.64 32.07 27.92
3 MDPI14352 56.10 30.04 21.35
a Inhibitors id from MDPI database.
b Free binding energy.
c Van der Waal energy.
d Coulomb energy.
Identification of novel inhibitors 113.5. Superimpose structure
The docked pose of Drug Bank hits and MDPI hits occupies
the ATP binding site. It was superimposed on crystal structure
(PDB ID: 3BLQ) that occupies this region. The binding pat-Figure 7 Selected inhibitors after screened Drug Bank database has
Please cite this article in press as: Hussain, A. et al., Identification of novel inhibitor
Saudi Journal of Biological Sciences (2015), http://dx.doi.org/10.1016/j.sjbs.2015.10.tern of Drug Bank hits and MDPI hits was found to be similar
to that of the ATP binding site. The figure clearly indicates
that the proposed binding pose is well occupied in the active
site of CDK9/Cyclin T1 complex and has a binding pattern
similar to that of ATP (Figs. 7 and 8).been superimposed in the ATP binding site of the target protein.
s against Cyclin Dependent Kinase 9/Cyclin T1 complex as: Anti cancer agent.
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Figure 8 Selected inhibitors after screened MDPI database has been superimposed in the ATP binding site of the target protein.
12 A. Hussain et al.4. Conclusion
Virtual screening is a powerful technique which is widely used
in the drug discovery as an initial phase in the medicinal chem-
istry research. The discovery of novel and potent inhibitors is
reported in this present study. It has been clearly confirmed
that the approach utilized in this study is successful in finding
eleven potent CDK9/Cyclin T1 inhibitors from Drug Bank
and MDPI databases. These inhibitors have shown drug-like
properties upon the ADMET and Lipinski’s rule of five. Com-
pound 4-{4-[4-(3-aminopropoxy) phenyl]-1H-pyrazol-5-yl}-6-
chlorobenzene-1,3-diol (DB08045) was showing high binding
affinity and docked perfectly within the binding pocket region
forming interaction with Cys106, Asp104, Lys48, Ile25,
Asn154, Asp167 with docking score 14.072. It is obvious that
these hits could be potent and selective anticancer agent
against Cyclin Dependent kinase/Cyclin T1 complex.
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